Biomarin Pharmaceutical Inc., of San Rafael, Calif., reported that it generated total revenues of $391.7 million for the third quarter, compared to $334.1 million for the quarter ending Sept. 30, 2017, an increase of 17 percent. Net product revenues were $386.3 million, compared to $298.8 million in 2017.